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The use of vitamin D3 analogues in combination with either
naturally occurring or synthetic retinoids may form an attractive
therapy for androgen-independent metastatic prostate cancer. To
investigate this potential, we have examined the effect of a potent
vitamin D3 analogue and a synthetic anti-activator protein 1 (anti-
AP-1) retinoid on clonal proliferation and investigated the possible
mechanism of the observed cooperative effects.
Prostate cancer has become the most frequently diagnosed, non-
skin cancer among American men and the second leading cause of
cancer mortality among this group (Parker et al, 1997). Despite the
increase in the incidence of the disease, no successful long-term
therapies exist if the cancer progresses beyond the prostate capsule.
Metastatic growth of prostate cancer tissue may be controlled, and
even a long-term remission induced, by blockade of endogenous
androgen stimulation. Unfortunately, the disease often re-emerges
within a few years in a lethal, poorly differentiated and androgen-
independent form. The shortage of curative therapies for such a
widespread disease has resulted in a large impetus to develop alter-
natives therapies. Drugs that have been intensively studied in
recent years are biological modifiers of growth, either alone or in
combinations to retard cell proliferation (Novichenko et al, 1995;
Campbell et al, 1998a), promote cell death (Danesi et al, 1994;
Welsh, 1994; Li et al, 1995; Planchon et al, 1995) and/or induce
differentiation of cells to a terminally mature, non-dividing stage
(Samid et al, 1993; Liu et al, 1994; Hseih et al, 1995).
Various potential biological modifiers have been investigated,
including the physiologically active metabolites of both vitamins
A and D (Niles, 1995; Kantarjian et al, 1996) namely all-trans-
retinoic acid (ATRA) and its isomer 9-cis-retinoic acid (9cRA) and
1a,25-dihydroxyvitamin D3 [1a,25(OH)2D3]. We and others have
shown that these compounds, at relatively high doses, can inhibit
the in vitro growth of cancer cells from several different tissues,
including prostate (Norman et al, 1990; Bollag, 1994; Lotan,
1994; Peehl et al, 1994; Feldman et al, 1995; Saunders et al, 1995;
Elstner et al, 1996; Campbell et al, 1997a).
One route by which vitamin D3 compounds and retinoids
mediate their activity is by binding with specific nuclear receptors;
for example 1 a,25(OH)2D3 interacts exclusively with the vitamin
D3 receptor (VDR); ATRA and 9cRA with the retinoic acid recep-
tors (RAR), and 9cRA also with the retinoid X receptor (RXR)
(Mangelsdorf et al, 1995). These nuclear receptors are part of the
steroid hormone superfamily and act as ligand-inducible transcrip-
tion factors. They exert specific cellular effects by binding to
hexameric response elements within the promoter/enhancer
regions and, thereby, regulating transcription of target genes, some
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that is interrupted during transformation, and that this combination may form the basis for treatment of some androgen-independent prostate
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School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UKof which are associated with inhibition of proliferation, induction
of differentiation or apoptosis. Evidence has also emerged that
these compounds work together, for example, the promoter of the
cyclin-dependent kinase inhibitor (CDKI) (p21wafl), which appears
to be important for many of the antiproliferative actions of these
compounds, has response elements for both 1a,25(OH)2D3
[vitamin D response element (VDRE)] and ATRA [retinoic acid
response element (RARE)] (Liu et al, 1996a, 1996b). Similarly,
we (Elstner et al, 1996) and others (Brown et al, 1994; Blutt et al,
1997) have demonstrated synergistic inhibition and differentiation
of various cancer cell lines by these drugs. Separate from the
transcriptional activation profile of 1a,25(OH)2D3 and ATRA are
other effects that appear to be associated with post-transcriptional
regulation of protein expression. For example, 1a,25(OH)2D3 has
been shown to increase expression of the CDKI p27kipl in HL-60
leukaemic cells by increasing the rate of mRNA translation and
extending protein half-life, but not by altering the mRNA level
(Hengst and Reed, 1996; Wang et al, 1996). Similar post-transcrip-
tional effects have been attributed to retinoids in the regulation of
another CDKI (p21wafl) (Schwaller et al, 1993; Li XS et al, 1996).
Steroid hormone receptors also appear to regulate indirectly
other transcriptional pathways via a mechanism known as AP-1
repression. Mitogens, such as cytokines, induce dimerization of
the AP-1 proteins, for example c-Jun and c-Fos, into an active
form which transactivates genes associated with growth. The
potential of this pathway to trigger unregulated growth has been
realized in cellular transformation involving Fos and Jun oncopro-
teins. The thyroid and RAR-a receptors participate in the normal
regulation of the AP-1 complex by down-regulating c-fos expres-
sion (Perez et al, 1993). The relationship between these two oppo-
site regulatory pathways allows for fine-tuning of responses with
the possibility of synergistic positive and negative effects
(Simonson, 1994; Alroy, 1995; Liu et al, 1995). Both sets of tran-
scriptional elements converge on the regulation of key growth
factors, thereby allowing their spatial and temporal expression.
For example, interleukin 2 and transforming growth factor b1 are
positively regulated by AP-1 proteins and negatively controlled by
ATRA (Salbert et al, 1993; De Grazi et al, 1994). Correspondingly,
deregulation of this process occurs in cancer cells, for example
retinoid-resistant breast cancer cell lines (e.g. BT-20) have a high
level of endogenous AP-1 activity (Burg et al, 1995), and osteo-
sarcomas may have abnormally high expression of osteocalcin as a
result of deregulated AP-1 activity (Jaaskelainen et al, 1994).
Clinical applications of 1a,25(OH)2D3 and ATRA alone at doses
that are pharmacologically active have been curtailed because of
side-effects. Vitamin D3 is limited to topical application, most
notably for the treatment of psoriasis, and although retinoids have
achieved remarkable success in the treatment of acute promyelocytic
leukaemia (APL) and the prevention of secondary lesions in individ-
uals with head and neck cancers (Huang et al, 1988; Hong et al,
1990), both vitamin analogues have toxicities. For example, many
potent vitamin D3analogues when injected into mice at doses that are
active in vitro produce lethal hypercalcaemia (Pakkala et al, 1995).
ATRA can produce skin, mucous membrane and hepatic toxicities as
well as a high teratogenicity (Morosetti and Koeffler, 1996).
Furthermore, over several months of ATRA therapy, APL cells
develop insensitivity to the differentiating effects of ATRA. This
resistance is multifactorial, which can include abnormal ligand
binding and altered transcriptional activation (Rosenauer et al, 1996).
We have previously discovered that the potent analogue of
vitamin D3 [1a,25-(OH)2-16-ene-23-yne-26,27-F6-19nor-D3 (code
name LH)] inhibits clonal proliferation of LNCaP, PC-3 and DU-
145 prostate cancer cells (Campbell et al, 1997a). Unfortunately,
this analogue also causes hypercalcaemia at high doses (Pakkala et
al, 1995). In a preliminary study to enhance the action of this
compound, we investigated combinations of LH with various
naturally occurring and receptor-selective retinoids that transacti-
vate through either RARE or RXRE (Campbell et al, 1998b) and
demonstrated that the capacity for synergistic effects was reduced
with increased cellular transformation. We have now investigated
a synthetic retinoid that has predominately anti-AP-1 effects, as
few anti-cancer studies have focused on the contribution of AP-1
repression to retinoid-mediated inhibitory effects. One such
retinoid is SR11238, which has approximately 100% of the anti-
AP-1 effect of ATRA but has minimal ability to transactivate
through a RARE (Fanjul et al, 1994). In this study, we show that
combined low doses of LH with SR11238 have prominent antipro-
liferative effects. We also examined the mechanism of this inhibi-
tion by considering various target proteins, such as p21(wafl) and
E-cadherin, which we and others have previously shown to be
modulated by vitamin D3 and retinoids in cancer cells (Liu et al,
1996; Munker et al, 1996; Campbell et al, 1997a,b). Their effects
on the induction of apoptosis and transactivation of the vitamin D
response element (VDRE) present in the upstream region of the
human osteocalcin gene were also examined.
MATERIALS AND METHODS
Cells
Human prostate cancer cell lines were obtained from ATCC
(Rockville, MD, USA) and maintained as recommended; LNCaP
was established from a metastatic lesion in the supraclavicular
lymph node of a patient with prostate cancer; PC-3 was derived
from a primary adenocarcinoma of the prostate; and DU-145 was
established from prostate cancer metastatic to the brain. LNCaP
was maintained in RPMI with 10% fetal calf serum (FCS); PC-3
and DU-145 were grown in Dulbecco’s modified Eagle medium
(DMEM) with 10% FCS.
Vitamin D3 analogues and retinoids
The vitamin D3 analogue [1a,25(OH)2-16-ene-23-yne-26,27-
F6-19-nor- D3, code name LH], ATRA, and the synthetic anti-AP-
1 retinoid [2-(4,4-dimethyl-3,4-dihydro-2H-1benzopyran-6-yl)-
carbonyl-2-(4-carboxyphenyl)-1,3,-dithiane] (SR11238) were kept
in stock vials at 10–3 M in ethanol at –20°C in the dark. For experi-
mental use, these solutions were diluted in normal medium imme-
diately before use.
Colony formation in soft agar
The antiproliferative potency of LH and retinoids was determined
by single- and combination-dose (10–9 M) studies in soft agar.
Trypsinized and washed single-cell suspensions of LNCaP, PC-3
and DU-145 prostate cancer cells from 80% confluent cultures
were enumerated and plated into 24-well, flat-bottomed plates
using a two-layer soft agar system with 1 ´ 103 cells in 400 ml of
media per well, as described previously (Munker et al, 1986). The
cells were grown in either RPMI or DMEM. Both layers were
prepared with agar (1%) equilibrated at 42°C. Before addition of
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(final concentration 10–9 M) were pipetted into the wells and then,
after this layer had set, the top layer containing cells was pipetted
into the wells. Stock solutions of LH, ATRA and SR11238 and the
experimental plates were kept in the dark to minimize UV-
catalysed degradation. After 14 days of incubation, the colonies 
(³ 50 cells) were counted using an inverted microscope. All exper-
iments were done at least three times in triplicate dishes per exper-
imental point. Dose–response studies with SR11238 were
undertaken in the same assay system.
Measurement of apoptosis
Combinations of LH and SR11238 were investigated for their
capacity to induce apoptosis of LNCaP, PC-3 and DU-145 cells.
These cells were exposed to either LH or SR11238 alone or a
combination of each at 10–7 M for 4 days, with fresh analogues
added at day 2. Total cells, both in the media and those adhering 
to the plastic, were harvested and fixed in 1% methanol-free
formaldehyde for 15 min and washed in phosphate-buffered saline
(PBS) (Li and Daryzynkiewcz, 1995). The cell concentration was
corrected to 1 ´ 106 cells ml–1 and fixed in 5 ml of 70% ethanol.
Single- and double-strand DNA breaks were labelled with
bromodeoxyuridine triphosphate (BrD-UTP) for 40 min at 37°C
with terminal transferase (Boehringer Mannheim, Indianapolis,
IN, USA). The cells were permeabilized with a 0.3% solution of
Triton-X 100 in 0.5% bovine serum albumin (BSA) in PBS, DNA
breaks were tagged by the incorporation of BrDU and then identi-
fied using a fluorescein isothiocyanate (FITC) conjugated anti-
BrDU antibody. Cells were stained with propidium iodide (PI) for
30 min, and green fluorescence was measured by FACS analysis at
510–550 nm.
Transactivation assays
PC-3 cells (1 ´ 107) were plated in normal media in culture dishes to
give 70% confluent cultures. The cells were washed and maintained
in DMEM with 10% charcoal-stripped fetal calf serum (CS-FCS) for
24 h before transfection, and then transfected overnight with 3 mg of
pBLCAT2 plasmid with the VDRE-containing region of the human
osteocalcin promoter, as described by Kuno et al (1994), and 3 mg of
cytomegalovirus (CMV) promoter luciferase plasmid (internal stan-
dard) in the presence of 18 mg of lipofectamine (Gibco, Grand Island,
NY, USA). After transfection, the cells were trypsinized, washed and
divided into groups which were cultured in DMEM with 10% CS-
FCS with either LH or SR11238 separately, each at 1 ´ 10–7 M, or
together at a combined concentration of 1 ´ 10–7 M (5 ´ 10–8 M each).
Treated and non-treated cultures were harvested after 48 h for chlo-
ramphenicol acetyltransferase (CAT) reporter assays. After measure-
ment of light production from luciferase and normalization of lysate
volume, CAT assays were performed as described previously
(Rosenthal, 1987). Relative intensities of acetylated and non-acety-
lated chloramphenicol were measured on an AMBIS 4000 image
analyser (Ambis, San Diego, CA, USA), and the percentage of
conversion was calculated. Increases in CAT activity were compared
with reporter gene activities in the absence of either retinoid or
vitamin D3 analogue. As controls for determination of the linear
region of CAT activity, two standards were used. As a negative
control, pBLCAT2 plasmid without the human osteocalcin VDRE
promotor region was used; and, as a positive control, a CAT plasmid
containing a CMV promoter region was used.
Analysis of protein expression
The effects of LH and SR11238 on the expression of p21(waf l) 
and E-cadherin were examined. We previously found that
significant increases in expression of p21(waf l) and E-cadherin
occurred after 96 h exposure of LNCaP cells to LH (Campbell 
et al, 1997b). We, therefore, examined the effects on subcon-
fluent cultures of LNCaP when exposed to LH and SR11238,
either alone (at 1 ´ 10–7 M each) or in combination (at 5 ´ 10–8 M
each) for 4 days. Lysates were compared with non-treated cells 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) as previously described (Zhang et al, 1995). Briefly,
extracts from 1.5 ´ 106 cells were boiled in sample buffer for 
5 min and loaded onto a 12.5% (p21(waf l)) or 7.5% (E-cadherin)
SDS-polyacrylamide gel. After electrophoresis at 150 V, the
proteins were transferred to Immobilon-P membrane (Millipore,
Bedford, MA, USA), blocked with Tris-buffered saline Tween 
20 (0.1%) (pH 7.5), 1% gelatin for 1 h, then incubated with
antibodies to either p21(waf l) (Oncogene Research Products,
Cambridge, MA, USA) or E-cadherin (Transduction Laboratories,
Lexington, KY, USA). The proteins were then detected using 
an enhanced chemiluminescence (ECL) system (Amersham Life
Sciences, Little Chalfont, Bucks, UK). Comparison of non-
specific, background, protein bands and staining of the membrane
with Ponceau S were used to adjust the level of lysate added to
ensure even loading of protein. Densitometry was performed 
on bands to quantify the changes in the expression of target
proteins.
Statistical analysis
The interactions of two compounds were assessed by measuring
the mean effect of either LH or retinoid acting alone ( ± s.e.m.).
The combination of the mean clonal inhibition for each compound
acting alone was the predicted combined effect. The mean
observed combined clonal inhibition was then compared with this
value using the Student’s t-test. Classification of the inhibitory
effects were as follows: synergistic effects were those with an
experimental value significantly greater than the predicted value,
additive effects were those in which the experimental value did not
significantly differ from the predicted value, subadditive effects
were those in which the experimental value was significantly less
than the predicated value and ‘squelching’ effects were those in
which the experimental value was significantly lower than either
agent acting alone.
Other statistical analyses were performed using the Student’s
t-test.
RESULTS
Effects of vitamin D3 analogue LH, ATRA and anti-AP-1
retinoid SR11238 on clonal proliferation of human
prostate cancer cells
Figure 1 shows the effects of these compounds either alone or in
combination at the relatively low dose of 10–9 M on the clonal
growth of prostate cancer cells. LH (10–9 M) inhibited 24 ± 2.6%
(mean  ± s.e.) clonal growth of LNCaP cells, and ATRA and
SR11238 (10–9 M) alone resulted in a mean colony inhibition of 
12 ± 5% and 11 ± 3.6% respectively. Together, LH and either
ATRA or SR11238 (10–9 M) synergistically inhibited growth by a
AP-1-mediated inhibition of prostate cancer cells 103
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with the non-treated control.
The PC-3 cells were less sensitive than LNCaP cells to the
combined effects of LH plus ATRA (mean inhibition was 
38%  ± 1.5%). However, the combination of LH plus SR11238
retained significant potency resulting in a synergistic inhibition of
clonal growth (62 ± 3.2%) (P < 0.05). In contrast, DU-145 cells
were insensitive to both of these combinations and, indeed,
displayed squelching effects with either combination. These
results are summarized in Table 1.
Separate dose–response studies of SR11238 alone revealed this
compound to be inactive against all three cell lines with less than
30% colony inhibition even at 10–6 M (data not shown).
Induction of apoptosis
Of the three prostate cancer cell lines, only LNCaP cells under-
went significant apoptosis in the presence of either LH or
SR11238. LNCaP cells underwent a small, but constant, level of
apoptosis under normal growth conditions (approximately 3%). In
the presence of LH, a small but statistically significant (P < 0.01)
increase in apoptotis occurred (mean 9.4 ± 0.6%). SR11238 alone
also significantly (P < 0.01) increased the adoptotic cells (11.5 ±
1.5%). The combination of LH and SR11238 did not significantly
differ from the predicted combined value and was considered an
additive effect.
Transduction through a VDRE
The human osteocalcin promoter contains a well-characterized
VDRE, which has a RXR and VDR half-sites, and a closely asso-
ciated AP-1 site. Studies have suggested that the Jun/Fos AP-1
complex is able to inhibit VDR binding to the VDRE, thereby
down-regulating gene expression (Jaaskelainen et al, 1994).
Therefore, we hypothesized that the synergistic inhibition by LH
and SR11238 may be due to the reduction in AP-1’s antagonism to
transactivation of the VDRE by VDR. Transient transfection
assays in PC-3 cells showed that LH and SR11238 alone (10–7 M)
resulted in a mean increase in CAT activity of 3.5-fold ± 0.25-fold
and 0.5-fold ± 0.06-fold respectively; whereas, the combination of
the two compounds did not significantly alter the CAT activity
from that of LH alone (mean 3.6-fold ± 0.12-fold increase over
control cells not exposed to ligand) (Figure 2).
Transactivation through VDRE-containing plasmid, in the
absence of ligand was not significantly greater than that achieved
through a minimal promoter-containing plasmid that lacked a
VDRE (data not shown).
p21(wafl) and E-cadherin protein expression
Analysis of the p21(wafl) protein expression revealed that only 
LH but not SR11238 modulated it, and the combination of 
both compounds was not greater than LH alone (data not shown).
E-cadherin expression was enhanced by both LH and SR11238
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Figure 1 Inhibition of clonal growth of prostate cancer cells exposed to LH,
ATRA and SR11238 alone or in combination (10–9 M). Results expressed as
per cent (mean ± s.e.m.) of non-treated control cells. Each point represents
the mean of at least three experiments with triplicate dishes. Cells were
treated with analogue LH, ATRA and SR11238 either separately at 10–9 M
each or together at 5 ´ 10–9 M each (total analogue concentration 10–9 M)
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Figure 2 Transactivation of a VDRE-CAT reporter construct. PC-3 cells
transiently transfected with the human osteocalcin CAT reporter construct
were exposed separately to analogue LH (10–6 or 10–7 M) and SR11238 (10–7
M) or together at 5 ´ 10–8 M each (total analogue concentration 10–7 M). CAT
activity was measured as described in the Materials and methods section
Table 1 Summary of clonal inhibition by the combinations of LH and
various retinoids
Clonal inhibition
Combination LNCaP PC-3 DU-145
ATRA + LHa Syn* Add Sque***
SR11238 + LH Syn* Syn** Sque*
aThe interactions of two compounds were assessed by measuring the means
of either LH or retinoid acting alone (± s.e.m.). The combination of the mean
clonal inhibition for each compound acting alone was the predicted
combined effect. The mean observed combined clonal inhibition was then
compared with this value using the Student’s t-test. Classification of the
inhibitory effects were as follows: synergistic effects were those with an
experimental value significantly greater than the predicted value, additive
effects were those in which the experimental value did not significantly differ
from the predicted value, subadditive effects were those in which the
experimental value was significantly less than the predicted value and
squelching effects were those in which the experimental value was
significantly lower than either agent acting alone. Sque, squelching effects;
Add, additive effects; Syn, synergistic effects. *P < 0.001; **P < 0.05;
***P < 0.01.separately at 10–7 M (210% and 250% increased expression respec-
tively, compared with untreated control). The combination of both
together at a total reagent concentration of 10–7 M (each at 5 ´ 10–8
M) produced a greater increase (350% increased levels compared
with untreated controls) (Figure 3).
DISCUSSION
In the present study, we attempted to enhance the pharmaceutical
index of the potent vitamin D3 analogue LH by combination treat-
ment with a conformationally restricted retinoid SR11238 that has
been reported to have the AP-1 repressive capacities of ATRA, but
not its ability to transactivate through the RARE (Fanjul et al,
1994). One of the more interesting findings of the present study
was the observation that LH plus SR11238 produced a dramatic,
synergistic inhibition of the LNCaP and PC-3 cells. Previously, we
have shown LH to be a potent growth inhibitor of prostate cancer
cells (Campbell et al, 1997a). In the current study, we found that,
although the retinoid SR11238 alone had very low inhibitory
activity, its combination with LH caused synergistic inhibition 
of proliferation. A similar finding was reported in a recent study
which showed that anti-AP-1 retinoids could be as potent as ATRA
at inhibiting transformation of murine JB6 cell (Li JJ et al, 1996).
The current study is of special note because the LNCaP and PC-3
cells were insensitive to SR11238 alone, but were significantly
inhibited by SR11238 in combination with LH.
AP-1 repression has been investigated intensively and the inhi-
bition of Jun/Fos-mediated gene transcription by steroid hormone
receptors has been demonstrated in several cell types (Simonson,
1994; Alroy, 1995; Liu et al, 1995). Similarly, synthetic anti-AP-1
retinoids and vitamin D3 analogues have been shown to repress
synergistically the TPA-induced AP-1 activity in MCF-7 breast
cancer cells (Chen et al, 1995). We explored how LH and SR11238
might be mediating their synergistic clonal growth inhibition of
LNCaP and PC-3 cells. To investigate this, we utilized a human
osteocalcin promoter with the VDRE and AP-1 sites in close prox-
imity attached to the CAT reporter gene. We hypothesized that if
LH and SR11238 acted synergistically to enhance VDRE-medi-
ated growth inhibition, we may observe a corresponding syner-
gistic increase in VDRE-mediated CAT activity. However, the LH
and SR11238 combination did not increase transactivation of the
VDRE-containing reporter. Similarly, we did not observe a syner-
gistic up-regulation, in the presence of both compounds, of p21(wafl)
expression, a protein whose gene has multiple VDRE sites within
its promoter region. Therefore, although the effects of LH and
SR11238 converge to inhibit clonal proliferation, these
compounds probably do not affect the same genomic targets. Thus,
we do not know, as yet, the mechanism by which SR11238 poten-
tiated the effect of LH.
The expression of E-cadherin was additively up-regulated in the
presence of LH and SR11238. This observation is of interest
because the loss or down-regulation of E-cadherin protein is
observed in many metastatic cancers of epithelial origin. In
prostate cancer, 50% of metastases have either low or no expres-
sion of E-cadherin (Umbas et al, 1992; Cheng et al, 1996);
whereas normal, differentiated prostate cells display high levels of
this protein. It has been suggested that the E-cadherin gene may
play a role in preventing metastasis and behave as a tumour
suppressor (Umbas et al, 1994). Taken together, E-cadherin is a
good marker of functional differentiation (Otto et al, 1993;
Campbell et al, 1997a,b). In the current study, up-regulation of 
E-cadherin may involve more than exclusively VDRE-mediated
pathways because SR11238 did not appear to affect a VDRE
reporter construct. Vitamin D3 has been shown to play a physio-
logical role with testosterone to regulate normal prostate cells
(Konety et al, 1996). Perhaps retinoids, acting in an anti-AP-1
capacity, also have a physiological role in the control of growth of
normal prostate cells.
The extent to which the anti-tumorigenic effects of ATRA are
mediated by an anti-AP-1 pathway is undetermined. Previously,
we have shown synergistic inhibition of prostate cancer cell prolif-
eration by LH and certain novel and naturally occurring retinoids,
and that a loss of synergistic inhibition correlated with loss of
expression of RAR-b (Campbell et al, 1998b). However, this
previous study was not able to assess to what extent the anti-AP-1
effects of retinoids contributed to the inhibitory behaviour. We
have now shown, using a similar experimental design, that the
contribution of these retinoid effects appears to be highly sig-
nificant because the effect of LH plus SR11238 was potent in
LNCaP and PC-3 cells, whereas that of LH and ATRA was only
synergistically inhibitory only in LNCaP cells. This is intriguing
because PC-3 cells are more transformed than LNCaP cells
(Carrol et al, 1993; Gaddipati et al, 1994; Issacs et al, 1994; Ewing
et al, 1995; Tamimi et al, 1996) and, in particular, do not express
RAR-b, whereas LNCaP cells do. This is possibly reflected by the
reduced sensitivity of PC-3 cells to LH and various retinoids as
found in the present study, and more comprehensively in the
previous one (Campbell et al, 1998b). Strikingly, in PC-3 cells,
antiproliferative potency appears to be retained by anti-AP-1
AP-1-mediated inhibition of prostate cancer cells 105
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Figure 3 Modulation of E-cadherin by LH and/or SR11238. Expression of
E-cadherin by LNCaP cells was compared with untreated control after
treatment with analogue LH and SR11238 either separately at 10–7 M each,
or together at 5 ´ 10–8 M each (total analogue concentration 10–7 M). (A) Cell
lysates were resolved by SDS-PAGE, and E-cadherin was detected by
Western blot analysis using the antibody described in Materials and
methods. (B) Densitometry was performed on the bands and expressed as
a percentage increase compared with non-treated controlretinoids in combination with LH. This finding suggests that anti-
AP-1 effects may contribute significantly to the anti-cancer effects
of certain retinoids and may be retained by androgen-independent
prostate cancer cells.
In summary, we have demonstrated a significant enhancement
of the anti-proliferative effects against androgen-sensitive
(LNCaP) and androgen-insensitive (PC-3) prostate cancer cells by
the combination, at low and more physiological doses, of a potent
vitamin D3 analogue and a synthetic anti-AP-1 retinoid. The mech-
anism of inhibition did not appear to be increased by up-regulation
of purely VDRE-mediated events, but included other cellular
events that may represent a convergence between several
signalling pathways, including, for example, increased expression
of E-cadherin.
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